EORTC 26053 / CATNON / NOA
Phase III trial on radio-chemotherapy of anaplastic gliomas without combined loss of 1p and 19q
The EORTC 26053 trial is investigating whether concomitant or subsequent chemotherapy with temozolomide to radiotherapy improves overall survival in patients with anaplastic glioma without combined loss of 1p and 19q. Patients may be included after biopsy and one or more previous surgical resections, such as for low-grade glioma. Because of the large number of patients, the CATNON trial is a cooperative project of several national and international study groups. In addition to the EORTC, the NCI of Canada, two American study consortia and the Australian COGNO, NOA is co-initiator of this study.
Prof. Dr. Wolfgang Wick, Heidelberg, is responsible for the relationship with the EORTC. He will be happy to provide you with detailed information on how to participate in EORTC studies.